Industry Trends Shaping Organ Transplantation The transplant field continues to evolve rapidly, driven by clinical innovation, policy changes, and a growing focus on patient-centered care. Here are a few trends worth watching: 1. Expanding the Donor Pool Greater use of donation after circulatory death (DCD), living donors, and broader acceptance criteria is helping address the organ shortage. 2. Advances in Organ Preservation New preservation techniques, including normothermic perfusion, are extending organ viability and improving transplant outcomes. 3. Focus on Equity in Access Efforts to reduce disparities in transplant access, across geography, race, and socioeconomic status, are gaining momentum through policy reform and improved allocation systems. 4. Growth of Multidisciplinary Care Models Transplant programs are increasingly integrating coordinated care teams to support patients across the full journey: from evaluation to long-term follow-up. 5. Evolution of Immunosuppression Strategies Ongoing innovation in immunosuppressive therapies aims to balance rejection prevention with fewer long-term side effects. 6. Regulatory & Policy Shifts Changes in allocation policies and oversight are reshaping how organs are distributed and how programs are evaluated. 7. The Big Picture The transplant ecosystem is becoming more collaborative, more efficient, and more patient-focused—while continuing to push the boundaries of what’s possible. What trends are you seeing in your organization or region? 👇 #Transplantation #Healthcare #MedTech #OrganDonation #HealthcareInnovation

#Highlycited A Decade of Pancreas Transplantation—A Registry Report 🏫 By Angelika Gruessner at Department of Medicine/Nephrology, SUNY Downstate Health Sciences University Medical Center, Brooklyn, NY, USA 💡 Advances in outcomes are driven by improved patient selection, surgical techniques, and immunosuppressive therapies, highlighting the ongoing evolution of transplant medicine. 🔗 Read the full article: https://brnw.ch/21x1OTm #Transplantation #PancreasTransplant #Diabetes #ClinicalResearch #Medicine #OpenAccess #MDPI #HealthcareInnovation

Our CEO David-Alexandre Gros, M.D., recently shared insights into the critical role that our novel #immunosuppression approach has played in helping advance the field of #transplant medicine with Dartmouth Alumni Magazine. In this article by Celine Choi, he discusses leading our clinical progress across #KidneyTransplantation, islet cell #transplantation, and xenotransplantation, Eledon’s mission for tegoprubart to become the cornerstone immunosuppression therapy across #transplant types, as well as how his Dartmouth education helped shape his career and drive his passion for helping patients. To learn more about how our immunosuppression approach differs from today’s standard of care, which has not changed in three decades, and the potential of advancing this field to expand access to lifesaving transplants during a critical donor organ shortage, check out the full article: https://lnkd.in/d4Q4UBUu

Is bridging therapy the key to higher transplant success rates? The short answer: Yes. For patients with advanced liver cancer, the gap between diagnosis and transplant eligibility can feel insurmountable. Dr. Venkatesh BS discusses how the clinical team at CAREVue Health™ and Madras Transplant Associates (MTA) bridges that gap. The Process: • Downstaging: Reducing tumor burden using targeted therapies. • TARE: Utilizing Trans-Arterial Radio-Embolization to localize treatment. • Eligibility: Moving patients back into the criteria for life-saving surgery. • Recurrence Prevention: Optimizing long-term outcomes post-transplant. At CAREVue Health™, our goal is to ensure that "advanced" doesn't mean "ineligible." Watch the full insight below. 👇 https://lnkd.in/deRyW3Aj #MedEd #Hepatology #LiverCancer #PrecisionMedicine #CAREVue #Cell2Cure #HealthTech

#34Lives is proud to join other leaders across the US in a new collaborative initiative, the Kidney Rescue and Perfusion Alliance (#KiRPA). This coordinated, multi-center alliance will focus on advancing kidney rescue, perfusion science and clinical application. We believe that this group can accelerate progress in advancing normothermic machine perfusion (NMP) for kidney transplantation in a way that is not possible with a less coordinated and collaborative effort. The Alliance will be organized around two teams: Basic Science and Translational Research and Clinical Research. Dr. Jacqueline Garonzik Wang, who is leading the initiative, states, “This is an exciting moment for kidney perfusion science. With the collective experience represented in this group, we have the opportunity to define best practices, generate impactful science, and expand access to transplantation by rescuing kidneys that might otherwise go unused.”   #34lives #nokidneyleftbehind #jacquelinegaronzikwang

What is unique about the area of Glomerular diseases is how we should interpret and use the guidelines while keeping in mind that patient populations and resources are extremely variable. As such, what is right in one area might be different in another area. Also, trials eventually have specific inclusion criteria that differ dramatically from the patients we encounter daily. Here is the importance of the paper below. Congratulations Salem Almaani

I am pleased to share our latest research published in the Annals of Interventional Pulmonology, where we explore the role of Transbronchial Lung Cryobiopsy (TBLC) as a strategic "diagnostic bridge" for patients on Veno-venous (V-V) ECMO.  In the critical care setting, we often face a diagnostic dilemma: a patient with refractory ARDS requires a histological diagnosis to guide treatment, but the risks of surgical lung biopsy are prohibitively high. Our study demonstrates that TBLC offers a feasible, less invasive alternative with high diagnostic yield. Key Highlights: Clinical Impact: In our index case, TBLC successfully established a diagnosis of organizing-phase Diffuse Alveolar Damage (DAD). Targeted Therapy: This histological clarity allowed us to transition from empirical treatment to targeted pulse steroid therapy, leading to successful ECMO decannulation and patient recovery. Safety Profile: Our systematic review of 30 cases across world literature found no procedure-related mortality, supporting the safety of this bedside intervention when performed by an experienced team.  This work reinforces that ECMO does not just sustain oxygenation—it provides the physiological stability needed to perform critical diagnostic maneuvers safely. Santhakumar SubramanianDr. Nagarjuna V Maturu Full Article: https://lnkd.in/gnrtsuda #Pulmonology #InterventionalPulmonology #ARDS #ECMO #KMCH #MedicalResearch #CriticalCare #Cryobiopsy

An Australian-first liver transplant technology has seen a 70% increase in transplant numbers in one of Perth’s biggest hospitals. https://lnkd.in/gSStER7E #LiverTransplant #MedicalInnovation #HealthcareInnovation

New SLK/KAL allocation rules show promising results: few patients needed SLK, many recovered kidney function after liver transplant alone, and outcomes after SLK and KAL were similar. #TXPforAll #Transplantation #OpenAccess tinyurl.com/yzz3k9uz

***𝐑𝐞𝐭𝐢𝐧𝐚 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐚𝐧𝐭𝐬 𝐢𝐧 𝐑𝐞𝐯𝐢𝐞𝐰*** The landscape of advanced dry AMD care is shifting rapidly with the arrival of geographic atrophy treatments. Geographic Atrophy treatment is a groundbreaking therapeutic approach that targets the complement system to slow down irreversible retinal cell death and progressive vision loss. 👁️ Explore expert-driven clinical trial insights, precise patient selection strategies, and real-world outcomes to help incorporate these novel, sight-preserving therapies into clinical management. #Retinology #Ophthalmology #GeographicAtrophy